Lower dose tested for advanced breast cancer treatment

NCT ID NCT03822468

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether a lower starting dose of the drug ribociclib (400 mg) works as well as the standard dose (600 mg) when combined with hormone therapy for advanced breast cancer. It involved 376 women whose cancer had spread or returned and who hadn't received prior treatment for advanced disease. The goal was to see if the lower dose could control the cancer effectively while potentially reducing side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Comprehensive Cancer Cntr Of Nevada

Henderson, Nevada, 89052, United States
Florida Retina Institute

Orlando, Florida, 32804, United States
Marin Cancer Care

Greenbrae, California, 94904, United States
Millennium Research Clin Develop

Houston, Texas, 77090, United States
Montefiore Medical Center

The Bronx, New York, 10467, United States
Mount Sinai School Of Medicine

New York, New York, 10029, United States
Nebraska Cancer Specialists

Omaha, Nebraska, 68154, United States
Nebraska Hematology Oncology P C

Lincoln, Nebraska, 68506, United States
New York Oncology Hematology

Albany, New York, 12208, United States
Northwest Medical Specialties

Tacoma, Washington, 98405, United States
Novartis Investigative Site

San Juan, J5402DIL, Argentina
Novartis Investigative Site

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site

Linz, 4010, Austria
Novartis Investigative Site

Salzburg, 5020, Austria
Novartis Investigative Site

Vienna, 1090, Austria
Novartis Investigative Site

Edegem, 2650, Belgium
Novartis Investigative Site

Namur, 5000, Belgium
Novartis Investigative Site

Natal, Rio Grande do Norte, 59075 740, Brazil
Novartis Investigative Site

Florianópolis, Santa Catarina, 88034 000, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 01317 000, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 04014-002, Brazil
Novartis Investigative Site

Goiânia, 74605-070, Brazil
Novartis Investigative Site

São José do Rio Preto, 15090 000, Brazil
Novartis Investigative Site

Plovdiv, 4004, Bulgaria
Novartis Investigative Site

Sofia, 1303, Bulgaria
Novartis Investigative Site

Sofia, 1756, Bulgaria
Novartis Investigative Site

Cambridge, Ontario, N1R 3G2, Canada
Novartis Investigative Site

Valledupar, Cesar Department, 5602310, Colombia
Novartis Investigative Site

Ibagué, Tolima Department, 730006, Colombia
Novartis Investigative Site

Bogotá, 110131, Colombia
Novartis Investigative Site

Bogotá, 110221, Colombia
Novartis Investigative Site

Montería, 230002, Colombia
Novartis Investigative Site

San José, 95008, Costa Rica
Novartis Investigative Site

Brno, Czech Republic, 656 53, Czechia
Novartis Investigative Site

Prague, 150 06, Czechia
Novartis Investigative Site

Helsinki, 00029, Finland
Novartis Investigative Site

Tampere, FIN-33521, Finland
Novartis Investigative Site

Besançon, 25030, France
Novartis Investigative Site

Caen, 14021, France
Novartis Investigative Site

Clermont-Ferrand, 63011, France
Novartis Investigative Site

Lyon 08, 69373, France
Novartis Investigative Site

Marseille, 13273, France
Novartis Investigative Site

Montpellier, 34298, France
Novartis Investigative Site

Saint-Herblain, 44805, France
Novartis Investigative Site

Strasbourg, F 67085, France
Novartis Investigative Site

Valenciennes, 59300, France
Novartis Investigative Site

Langen, Hesse, 63225, Germany
Novartis Investigative Site

Augsburg, 86150, Germany
Novartis Investigative Site

Berlin, 13581, Germany
Novartis Investigative Site

Bonn, 53111, Germany
Novartis Investigative Site

Dresden, 01127, Germany
Novartis Investigative Site

Dresden, 01307, Germany
Novartis Investigative Site

Essen, 45136, Germany
Novartis Investigative Site

Tübingen, 72076, Germany
Novartis Investigative Site

Weiden, 92637, Germany
Novartis Investigative Site

Budapest, H 1122, Hungary
Novartis Investigative Site

Debrecen, 4032, Hungary
Novartis Investigative Site

Szolnok, H-5000, Hungary
Novartis Investigative Site

Raipur, Chhattisgarh, 492001, India
Novartis Investigative Site

Nagpur, Maharashtra, 441108, India
Novartis Investigative Site

Bhubaneshwar, Odisha, 751007, India
Novartis Investigative Site

Delhii, 110 085, India
Novartis Investigative Site

Mumbai, 400 012, India
Novartis Investigative Site

Amman, 11941, Jordan
Novartis Investigative Site

Kaunas, LTU, LT 50161, Lithuania
Novartis Investigative Site

Vilnius, LT-08660, Lithuania
Novartis Investigative Site

Trujillo, La Libertad, 13011, Peru
Novartis Investigative Site

San Borja, Lima region, 41, Peru
Novartis Investigative Site

San Isidro, Lima region, 27, Peru
Novartis Investigative Site

San Miguel, Lima region, 32, Peru
Novartis Investigative Site

Lisbon, 1400-038, Portugal
Novartis Investigative Site

Loures, 2674514, Portugal
Novartis Investigative Site

Porto, 4200-072, Portugal
Novartis Investigative Site

Arkhangelsk, 163045, Russia
Novartis Investigative Site

Moscow, 111123, Russia
Novartis Investigative Site

Moscow, 115478, Russia
Novartis Investigative Site

Saint Petersburg, 197758, Russia
Novartis Investigative Site

Cape Town, 7500, South Africa
Novartis Investigative Site

Johannesburg, 2196, South Africa
Novartis Investigative Site

Parktown, 2193, South Africa
Novartis Investigative Site

Stockholm, 112 19, Sweden
Novartis Investigative Site

Stockholm, SE-118 83, Sweden
Novartis Investigative Site

Uppsala, 751 85, Sweden
Novartis Investigative Site

Bangkok, 10700, Thailand
Novartis Investigative Site

Chiang Mai, 50200, Thailand
Rocky Mountain Cancer Centers

Longmont, Colorado, 80501, United States
Southern Cancer Center PC

Mobile, Alabama, 36608, United States
Texas Oncology

McAllen, Texas, 78503, United States
Weinberg Cancer Institute at FSH

Baltimore, Maryland, 21237-3998, United States

Conditions

Explore the condition pages connected to this study.

BREAST CANCER